A Multi-Center, Randomized, Double-Blind, Parallel Group Study To Compare The Efficacy And Tolerability Of Valdecoxib And Diclofenac In Patients With A Sprained Ankle
This study has been completed.
Sponsor:
Pfizer
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00671320
First received: March 31, 2008
Last updated: April 30, 2008
Last verified: April 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To determine whether valdecoxib 40 mg twice a day the first day and then 40mg once a day until Day 7, was at least as effective as diclofenac 75 mg twice a day for 7 days, in treating acute first or second degree ankle sprain. The study also compared valdecoxib and diclofenac with respect to time to onset of pain relief (measured after the first dose), tolerability (adverse events) and time to return to Normal Function/Activity, among other measures.
| Condition | Intervention | Phase |
|---|---|---|
|
Pain Sprains and Strains Sprain |
Drug: valdecoxib Drug: diclofenac |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Multi-Center, Randomized, Double-Blind, Parallel Group Study To Compare The Efficacy And Tolerability Of Valdecoxib Vs. Diclofenac In Ankle Sprain |
Resource links provided by NLM:
Further study details as provided by Pfizer:
Primary Outcome Measures:
- Patient's assessment of ankle pain VAS [ Time Frame: Day 4 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Time to onset of pain relief [ Time Frame: 0, 15, 30, 45, and 60 minutes after first dose ] [ Designated as safety issue: No ]
- Physician's global assessment of ankle injury [ Time Frame: Days 1, 4, and 7 ] [ Designated as safety issue: No ]
- Patient's global assessment of ankle injury [ Time Frame: Days 1, 4 and 7 ] [ Designated as safety issue: No ]
- Patient's assessment of normal function/activity [ Time Frame: Days 1 to 7 ] [ Designated as safety issue: No ]
- Patient's and physician's satisfaction assessments [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
- Patient's assessment of ankle pain on visual analogue scale (VAS) [ Time Frame: Days 1 to 7 ] [ Designated as safety issue: No ]
| Enrollment: | 202 |
| Study Start Date: | December 2002 |
| Study Completion Date: | October 2003 |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Arm 1 |
Drug: valdecoxib
valdecoxib 40 mg tablet by mouth twice daily (BID) on Day 1 and then once daily (QD) on Days 2 to 7
|
| Active Comparator: Arm 2 |
Drug: diclofenac
diclofenac 75 mg capsule by mouth twice daily (BID) for 7 days
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients had sprained their ankle within 48 hours
- The sprain was a first or second degree ankle sprain of the lateral aspect, specifically: anterior talofibular ligament and/or calcaneofibular ligament
- At presentation patients were to have had moderate-severe ankle pain, (i.e., patient's assessment of ankle pain, on full weight bearing, using a 100 mm visual analog scale (VAS) was ≥ 45 mm), have a minimum rating of 2 on the Patient's Global Assessment of Ankle Injury and Patient's Assessment of Normal Function/Activity
- Investigator must have thought that the patient required and was eligible for therapy with an anti-inflammatory agent and/or analgesic to control symptoms
Exclusion Criteria:
- Women who were not post-menopausal or surgically sterilized, or who had have a positive urine pregnancy test prior to randomization and/or were not using adequate contraception according to the judgment of the Investigator
- Patients with a similar injury of the same joint within the last 6 months
- Clinical evidence of complete rupture of ankle ligaments (third degree sprain), required bed rest, hospitalization, surgical intervention for the ankle injury or non-removable full cast, bilateral occurrence of ankle injury or ankle and knee injury on the same side
- Patients with esophageal, gastric or duodenal ulcer within 30 days prior to randomization or had active GI or other disease that in the opinion of the investigator would preclude safe participation by the subject in the study.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00671320
Locations
| Argentina | |
| Pfizer Investigational Site | |
| Avellaneda, Buenos Aires, Argentina, 1872 | |
| Pfizer Investigational Site | |
| San Isidro, Buenos Aires, Argentina, 1642 | |
| Pfizer Investigational Site | |
| Buenos Aires, Argentina | |
| Chile | |
| Pfizer Investigational Site | |
| Santiago, RM, Chile | |
| Pfizer Investigational Site | |
| Santiago, Chile | |
| Colombia | |
| Pfizer Investigational Site | |
| Medellin, Antioquia, Colombia, (574) 5141516 | |
| Pfizer Investigational Site | |
| Bogota, Cundinamarca, Colombia, (57) 310-2322198 | |
| Pfizer Investigational Site | |
| Bogota, Cundinamarca, Colombia, (57) 310-8849622 | |
| Pfizer Investigational Site | |
| Bogota, Cundinarmarca, Colombia, (571) 6 164278 | |
| Pfizer Investigational Site | |
| Bucaramanga, Santander, Colombia, (577) 6 395409 | |
| Pfizer Investigational Site | |
| Cali, Valle del Cauca, Colombia, (57) 315-5410469 | |
| Pfizer Investigational Site | |
| Calli, Valle del Cauca, Colombia, (57) 310-8259712 | |
| Mexico | |
| Pfizer Investigational Site | |
| Monterrey, Nuevo Leon, Mexico, 64460 | |
| Peru | |
| Pfizer Investigational Site | |
| Lima, Peru | |
| Pfizer Investigational Site | |
| Lima, Peru, 27 | |
Sponsors and Collaborators
Pfizer
Investigators
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
Additional Information:
No publications provided
| Responsible Party: | Director, Clinical Trial Disclosure Group, Pfizer, Inc. |
| ClinicalTrials.gov Identifier: | NCT00671320 History of Changes |
| Other Study ID Numbers: | VALA-0513-146, A3471037 |
| Study First Received: | March 31, 2008 |
| Last Updated: | April 30, 2008 |
| Health Authority: | Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica |
Keywords provided by Pfizer:
|
acute ankle sprain, acute pain, South America |
Additional relevant MeSH terms:
|
Sprains and Strains Wounds and Injuries Diclofenac Valdecoxib Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Pharmacologic Actions Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Central Nervous System Agents Cyclooxygenase 2 Inhibitors |
ClinicalTrials.gov processed this record on May 19, 2013